SCHEMBL4551503

SCHEMBL4551503

CNc1ncc2cc(-c3cc(NC(=O)Nc4ccc(Cl)c(C(F)(F)F)c4)c(F)cc3C)c(=O)n(C)c2n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 6/20 0.65
RAF1 P04049 5/20 0.65
KDR P35968 4/20 0.49
MAPK14 Q16539 4/20 0.49
LCK P06239 1/20 0.49
JAK3 P52333 1/20 0.49
CDK8 P49336 2/20 0.48
SRC P12931 4/20 0.47
FGFR1 P11362 3/20 0.47
EGFR P00533 2/20 0.47
SYK P43405 1/20 0.47
CCNC P24863 1/20 0.46
PDGFRB P09619 3/20 0.46
PDGFRA P16234 3/20 0.46
STAT5A P42229 1/20 0.46
ACVR1 Q04771 1/20 0.46
PKMYT1 Q99640 1/20 0.46
TRPV1 Q8NER1 4/20 0.46
ABL1 P00519 3/20 0.44
KRAS P01116 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4553219 0.89 KDR (0.51) BRAFRAF1KDRMAPK14LCK
SCHEMBL4280813 0.88 BRAF (0.66) BRAFRAF1KDRMAPK14LCK
SCHEMBL4563553 0.86 BRAF (0.53) BRAFRAF1KDRMAPK14SRC
SCHEMBL5065289 0.86 BRAF (0.66) BRAFRAF1KDRMAPK14LCK
SCHEMBL4552825 0.86 BRAF (0.66) BRAFRAF1KDRMAPK14SRC
SCHEMBL5063022 0.84 RAF1 (0.68) BRAFRAF1MAPK14SRCFGFR1
SCHEMBL5065339 0.84 RAF1 (0.68) BRAFRAF1MAPK14SRCFGFR1
SCHEMBL5065390 0.84 BRAF (0.70) BRAFRAF1KDRMAPK14LCK
SCHEMBL5065267 0.84 BRAF (0.68) BRAFRAF1KDRMAPK14SRC
SCHEMBL4422767 0.84 BRAF (0.68) BRAFRAF1KDRMAPK14SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US claimed
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
EP-2063897-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 EP disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed
WO-2008034008-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC. (US) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885KDR 500/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885KDR 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.